整合离体胎盘转运与PBPK模型预测胎儿达芦那韦暴露
本研究将人离体胎盘灌注获得的达芦那韦/利托那韦胎盘清除率整合入妊娠PBPK模型,模拟足月胎儿达芦那韦暴露。结果显示母体达芦那韦600/100 mg每日两次给药时,胎儿群体谷浓度高于或接近耐药病毒半数有效浓度0.55 mg/L,提示胎儿暴露具有治疗意义。
要点
- 离体胎盘灌注测得母胎清除率0.91±0.11 mL/min,胎母清除率1.6±0.3 mL/min(n=6)。
- 整合胎盘转运的PBPK模型可用于评估胎儿药物暴露与毒性。
核心结论
- 母体口服达芦那韦后胎儿群体暴露具有治疗意义,可能有助于预防HIV母婴传播。
研究设计与样本
- 在已验证的妊娠PBPK模型中扩展胎儿-胎盘单元,用离体人绒毛叶灌注模型测定胎盘清除率(n=6次灌注)进行参数化。
主要发现
- 母胎绒毛叶清除率平均±标准差为0.91±0.11 mL/min,胎母清除率为1.6±0.3 mL/min(n=6次灌注)。
- 达芦那韦600/100 mg每日两次给药时,预测胎儿最大血浆浓度1.1 mg/L、谷浓度0.57 mg/L、达峰时间3 h、半衰期21 h。
关键数值与推荐
- 胎儿群体谷浓度高于或接近耐药病毒达芦那韦半数有效浓度0.55 mg/L。
临床怎么用
- 该整合方法可用于评估胎儿药物暴露,辅助预防胎儿毒性或开发更具胎儿选择性的治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fetal antiretroviral exposure is usually derived from the cord-to-maternal concentration ratio. This static parameter does not provide information on the pharmacokinetics in utero, limiting the assessment of a fetal exposure-effect relationship. OBJECTIVE: The aim of this study was to incorporate placental transfer into a pregnancy physiologically based pharmacokinetic model to simulate and evaluate fetal darunavir exposure at term. METHODS: An existing and validated pregnancy physiologically based pharmacokinetic model of maternal darunavir/ritonavir exposure was extended with a feto-placental unit. To parameterize the model, we determined maternal-to-fetal and fetal-to-maternal darunavir/ritonavir placental clearance with an ex-vivo human cotyledon perfusion model. Simulated maternal and fetal pharmacokinetic profiles were compared with observed clinical data to qualify the model for simulation. Next, population fetal pharmacokinetic profiles were simulated for different maternal darunavir/ritonavir dosing regimens. RESULTS: An average (±standard deviation) maternal-to-fetal cotyledon clearance of 0.91 ± 0.11 mL/min and fetal-to-maternal clearance of 1.6 ± 0.3 mL/min was determined (n = 6 perfusions). Scaled placental transfer was integrated into the pregnancy physiologically based pharmacokinetic model. For darunavir 600/100 mg twice a day, the predicted fetal maximum plasma concentration, trough concentration, time to maximum plasma concentration, and half-life were 1.1, 0.57 mg/L, 3, and 21 h, respectively. This indicates that the fetal population trough concentration is higher or around the half-maximal effective darunavir concentration for a resistant virus (0.55 mg/L). CONCLUSIONS: The results indicate that the population fetal exposure after oral maternal darunavir dosing is therapeutic and this may provide benefits to the prevention of mother-to-child transmission of human immunodeficiency virus. Moreover, this integrated approach provides a tool to prevent fetal toxicity or enhance the development of more selectively targeted fetal drug treatments.
引用
- Schalkwijk S, Buaben AO, Freriksen JJM, et al. Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling. Clin Pharmacokinet. 2018. PMID: 28744795. doi:10.1007/s40262-017-0583-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。